Microbiology Core

微生物学核心

• 批准号: 7746174
• 负责人: JAN S. ERIKSON
• 金额: $ 18.59万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2014-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7746174
• 关键词: Address; Animals; Antiviral Agents; B-Lymphocytes; Bacteria; Bacterial Infections; Bacterial Pneumonia; Bacteriophages; Biological Assay; CD4 Positive T Lymphocytes; Complication; Data; Development; Effectiveness; Ensure; Environment; Experimental Designs; Future; Goals; Human; Immunity; Immunologic Memory; Individual; Infection; Infectious Agent; Inflammation; Inflammatory; Location; Microbiology; Modeling; Monitor; Morbidity - disease rate; Procedures; RNA Viruses; Recombinants; Reproducibility; Research Project Grants; Respiratory System; Respiratory Tract Infections; Respiratory tract structure; Shapes; Standardization; Streptococcus pneumoniae; T-Lymphocyte; Testing; Tissues; Vaccines; Viral; Viral Load result; Virus; Virus Diseases; improved; influenza virus strain; influenza virus vaccine; influenzavirus; mortality; novel; pandemic disease; pandemic influenza; pathogen; programs; respiratory; tool; vaccination strategy

Viral infections remain a considerable cause of morbidity and mortality. Despite advances in the availability of vaccines, the mechanisms of generating and maintaining effective antiviral immunity remains incompletely understood. A major concern in this regard is influenza virus, a focal point for a number of Projects in this Program. The vaccine for influenza virus must be remade each year because it has not yet been possible to generate broadly protective immunity to this rapidly evolving RNA virus and the potential emergence of devastating pandemic influenza virus strains remains ever present. Thus, it is essential that we understand the basic principles of long-term B cell and T cell immunity to viral infections, including influenza virus, to improve existing, and develop novel, vaccination strategies. A major complication with influenza virus infection is co-infection with bacteria resulting in bacterial pneumonia. It is unclear how such a co-infection with a virus and bacterial pathogen in the respiratory tract impacts antiviral immunological memory and future protective immunity to the virus. To address these questions, the research Projects will utilize common infectious agents. The overall goal of Core B is to generate, standardize, store and provide infectious agents to the Projects. In addition, Core B will optimize and validate assays to monitor the burden of infectious agents in tissues from infected animals. Thus, the specific Aims for this core are: 1) To define a model of respiratory infection with Streptococcus pneumonia (Sp) and coinfection with Sp and influenza virus; 2) To generate and characterize Streptococcus pneumoniae expressing CD4 T cell determinant(s) from influenza virus HA; and 3) To produce, standardize, maintain and store infectious agents. The activities of this Core will therefore create synergy and interaction between the different Projects by creating a common and easily accessible set of tools, and by enhancing the quality, standardization and reproducibility of the data generated by the individual Projects.

病毒感染仍然是发病率和死亡率的重要原因。尽管可用性进步 在疫苗中，产生和维持有效抗病毒免疫的机制仍然不完全 理解。这方面的主要问题是流感病毒，这是许多项目的重点 程序。每年必须重新生产流感病毒的疫苗，因为尚无可能 对这种快速发展的RNA病毒产生广泛的保护性免疫，并具有 毁灭性的大流行性流感病毒菌株仍然存在。因此，我们必须了解 长期B细胞和T细胞免疫对病毒感染的基本原理，包括流感病毒， 改善现有的，并制定新颖的疫苗接种策略。流感病毒的主要并发症 感染是与细菌共同感染，导致细菌性肺炎。目前尚不清楚这种共同感染如何 呼吸道中的病毒和细菌病原体会影响抗病毒免疫记忆和 对病毒的未来保护性免疫。为了解决这些问题，研究项目将使用 常见的传染剂。核心B的总体目标是生成，标准化，存储和提供 这些项目的传染性代理商。此外，核心B将优化和验证测定法以监控负担 来自感染动物的组织中的感染剂。因此，该核心的具体目的是：1）定义 肺炎链球菌（SP）的呼吸道感染模型，并与SP和流感共同感染 病毒; 2）生成和表征表达CD4 T细胞决定簇的肺炎链球菌 来自流感病毒HA； 3）生产，标准化，维护和存储传染性药物。活动 因此，该核心将通过创建一个不同项目之间的协同作用和互动 通用且易于访问的工具集，并通过增强质量，标准化和可重复性 单个项目生成的数据。